AzTrials
AzTrials

Periodontal DiseasesENDS-SRPNCT05745324

The Effect of Scaling and Root Planing on Oral Inflammatory Biomarkers Among E-cig Users and Non-smokers

A study testing Scaling and root planing in people with Periodontal Diseases and Smoking, run by Kuwait University at 1 site in Kuwait.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background/Aim: There are no studies that have compared the gingival crevicular fluid (GCF) levels of IL-1β in non-smokers (NS) and electronic nicotine delivery system (ENDS)-users before and after scaling and root planing (SRP) in patients with gingivitis. Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Periodontal Diseases, Smoking
What is being tested?
Scaling and root planing
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteKuwait
Study dates
1 Jun 2021to 1 Dec 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • The inclusion criteria: ENDS-users, cigarette smokers, non-smokers, age (18-60), gender (men), periodontal health status (gingivitis/periodontitis), having minimum number of 20 teeth, and medically healthy.

Who cannot join

  • The exclusion criteria: Patients who did scaling and root planing in the past 3 months.

Trial locations and contacts

1 site in 1 country.

Kuwait1 site
  • Faculty of Dentistry

    Kuwait City, 13110

Other trials in Kuwait

About this study

Official title: The Effect of Scaling and Root Planing on Gingival Crevicular Fluid and Salivary Levels of Inflammatory Biomarkers Among Electronic Nicotine Delivery Systems User, Smokers and Non-Smokers

Background/Aim: There are no studies that have compared the gingival crevicular fluid (GCF) levels of IL-1β in non-smokers (NS) and electronic nicotine delivery system (ENDS)-users before and after scaling and root planing (SRP) in patients with gingivitis. The aim of the present study is to compare the effect of scaling and root planing on the expression of IL-1β in the GCF among ENDS-users and NS clinically.

Methods: Self-reported current ENDS users and NS would be included. A questionnaire would be used to collect demographic data. All patients would undergo SRP. Clinical measures, periodontal parameters [probing depth (PD), plaque index (PI), and bleeding on probing (BOP)], and GCF IL-1β would be measured at baseline. At 1-week (T1) and 3 weeks (T2) of follow-up, periodontal parameters and GCF IL-1β levels would be re-assessed.

Read the detailed description

2.1. Ethical approval Ethical approval was obtained from the Ethics Committee of Health Sciences Center at Kuwait University. All volunteering individuals were requested to read and sign a consent form written in simple English and Arabic.

2.2. Study Area/Setting The present longitudinal study was conducted between November 2021 and September 2022 at the Kuwait University Dental Center (KUDC). The study participants were regular patients attending the KUDC and the sampling design was convenience sampling.

2.3. Selection Criteria The inclusion criteria: ENDS-users, non-smokers, age (18-25), gender (men), periodontal health status (gingivitis), having minimum number of 20 teeth, and medically healthy. The exclusion criteria: Patients who did scaling and root planing in the past 3 months, T-cigs smokers, and dual smokers.

2.4. Data Collection Methods, Instrument Used, Measurements A standardized questionnaire including a consent form was used to gather information regarding gender, age (in years), nationality, marital status, highest level of education, oral hygiene status, last dental visit, last time that scaling and root planing was done, smoking status, type of smoked product, duration of ENDS usage (in years), frequency of ENDS usage per day, number of ENDS puffs taken per session, family smoking history, exposure to secondhand smoke, general health status, and attitude towards smoking.

2.5. Blinding

2.6. Study Participants Twenty current ENDS-users and eighteen NS were recruited to participate in this study. All participants were requested to refrain from eating and using any oral hygiene method for at least 3 hours prior to their visit.

2.7. Sample Collection For screening of subjects for their use of tobacco products, saliva was collected and tested for the content of nicotine using chairside test kits (NicAlert, Confirm Bioscience, CA, USA). Unstimulated saliva (UWS) was collected before clinical assessment using non-invasive techniques. Prior to salivary and GCF samples collection, each participant's vital signs were measured and recorded. The participants were asked to rinse their mouth with water before a baseline salivary sample is collected to measure cotinine levels. Each participant was asked to collect saliva passively in their mouth and expectorate in a tube every one minute until three millimeters of saliva is collected. The tubes were then stored at -80°C. After that, GCF samples were collected using filter paper strips. GCF will be sampled from four sites at fully erupted, caries-free permanent molars (mesiobuccal and distobuccal of each molar) with gingival index (GI) score of 2 or 3 for gingivitis group. Scaling and root planing was provided for each participant and saliva and GCF samples were obtained in the same manner explained previously after one week and three weeks.

2.8. Power Analysis Power analysis was determined using a computer software (nQuery Advisor 6.0, Statistical Solutions, Saugas, MA., USA) with an alpha and effect size of 0.05 and 0.3, respectively. Sample size estimation was based on the presumption that a mean difference of 1 mm in clinical AL and PD should be detected at a significance-level of 0.05 and a desired study power of at least 80%. It was estimated that a sample size of at least 20 patients/group would achieve 95% study power with a 0.05 two-sided significance-level.

2.9. Analysis of Cotinine and IL-1β in GCF Saliva levels of cotinine was measured to determine the electronic cigarettes status using a high sensitivity, quantitative enzyme immunoassay (ELISA) kit. Then, IL-1β GCF levels was analyzed using commercially available ELISA kit. The difference in the levels of the biomarker before and after the intervention will provide an insight of the soft tissue response to the treatment. This will show the deleterious effect of electronic nicotine delivery systems on the soft tissue response to therapy.

2.10. Clinical Examination In all patients, Löe \& Silness gingival index (GI)(Löe and Silness 1963) and Silness \& Löe plaque index (PI)(Silness and Löe 1964) were recorded.

2.11. Statistical Analysis Statistical analyses was done using SPSS software (SPSS Version 26, Chicago, IL., USA).

Being tested
Scaling and root planing
Keywords
electronic cigarettes
Medical subject headings
Periodontal Diseases, Smoking, Vaping

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Scaling and root planingProcedure or surgery

    SRP is cleaning the sub gingival and supra gingival plaque and calculus from the teeth

Study groups in NCT05745324
Study groupRoleWhat they receive
Smoker vs NonsmokersExperimentalSRP would be performed for Smokers (ENDS and conventional cigarette) and Nonsmokers and their inflammatory biomarkers would be assessed.
Receives: Procedure: Scaling and root planing
ENDS users and NonsmokersExperimentalSRP would be performed for ENDS users and Nonsmokers and their inflammatory biomarkers would be assessed.
Receives: Procedure: Scaling and root planing
Smokers with periodontitis and NonsmokersExperimentalSRP would be performed for Smokers with periodontitis and health nonsmokers and their inflammatory biomarkers would be assessed.
Receives: Procedure: Scaling and root planing
Smokers with periodontitis and Nonsmokers with periodontitisExperimentalSRP would be performed for Smokers and Nonsmokers with periodontitis and their inflammatory biomarkers would be assessed.
Receives: Procedure: Scaling and root planing

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical Attachment Level

    Level of gingival attachment would be assessed

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Feb 2023
  2. Study start1 Jun 2021
  3. Primary completion1 Jun 2023
  4. Study completion1 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Care provider, Investigator, Outcomes assessor
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05745324
Sponsor's protocol ID
VDR/ED/14
Acronym
ENDS-SRP
Status last verified
Jul 2024
First submitted
16 Feb 2023
Last updated
8 Jul 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Alkhalifah AB, Alfuraih NT, Joseph B, Baskaradoss JK. Effect of scaling on levels of interleukin 1-beta and clinical periodontal parameters among e-cigarette users and non-smokers: A prospective study. Tob Induc Dis. 2024 Jul 10;22:10.18332/tid/189552. doi: 10.18332/tid/189552. eCollection 2024.

    PubMed 38988743

Questions about this trial

What is this clinical trial studying?

A study testing Scaling and root planing in people with Periodontal Diseases and Smoking, run by Kuwait University at 1 site in Kuwait.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Kuwait. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical Attachment Level (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05745324, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in